 RARITAN, N.J., Sept. 14, 2021 GLOBE NEWSWIRE -- Ortho Clinical Diagnostics Holdings plc Nasdaq: OCDX the Company, one of the worlds largest pure-play in vitro diagnostics companies, today announced the closing the Closing of the previously announced underwritten secondary offering of 25,300,000 of the Companys ordinary shares held by a selling shareholder affiliated with The Carlyle Group the Selling Shareholder, which includes the full exercise by the underwriters of their option to purchase up to 3,300,000 additional ordinary shares, at a price of 17.50 per share. As a result of the Closing, the Company is no longer a controlled company within the meaning of the rules of the NASDAQ Global Select Market. 